Impact Of RA Therapy Compliance On Patient-Reported Outcomes

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01438892

Enrollment

396

Registered

2011-09-22

Start date

2012-02-29

Completion date

2013-01-31

Last updated

2013-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Keywords

rheumatoid arthritis, therapy compliance

Brief summary

Several observational studies have evaluated the comparative treatment costs associated with each agent, particularly those within the anti-TNF class, but few have evaluated the impact of therapy compliance, persistence, treatment patterns on patient reported outcomes, healthcare utilization and costs, using a provider database. This study is designed to fill in this information gap.

Detailed description

Cohort observational

Interventions

DRUGtDMARDs

Traditional DMARDs for RA

DRUGbiodmards

Biologic DMARDs

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adults with moderate to severe RA who are currently using a DMARD

Exclusion criteria

* Psoriatic Arthritis (PsA), Psoriasis (PsO), SSystemic Lupus Erythematosus (SLE), Non-Disease modifying anti-rheumatic disease (non-DMARD) use

Design outcomes

Primary

Measure	Time frame
HAQ	12 months
36-Item Short-Form Health Survey (SF-36)	12 months

Secondary

Measure	Time frame
Compliance	12 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026